Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.
about
Intestinal microbiota link lymphopenia to murine autoimmunity via PD-1+CXCR5-/dim B-helper T cell inductionPathways leading to an immunological disease: systemic lupus erythematosus.Human Immunodeficiency Virus Playing Hide-and-Seek: Understanding the TFH Cell Reservoir and Proposing Strategies to Overcome the Follicle SanctuaryLow-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.Gene therapy with an AAV vector expressing human IL-2 alters immune system homeostasis in humanized mice.Plasmablasts with a mucosal phenotype contribute to plasmacytosis in SLE.CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancerRegulatory T Cells in SLE: Biology and Use in Treatment.Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice.Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukin-2.Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity.Novel Treatments in Lupus.T cells and autoimmune kidney disease.Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.The rise of IL-2 therapy - a picture beyond Treg cells.PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.Regulatory T cells in Acute and Chronic Kidney Diseases.The γ c family of cytokines: fine-tuning signals from IL-2 and IL-21 in the regulation of the immune response.IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors.Counteracting dysfunction of regulatory T cells in organ transplantation.Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.An era of biological treatment in systemic lupus erythematosus.The effect of interleukin (IL)-21 and CD4+ CD25++ T cells on cytokine production of CD4+ responder T cells in patients with myasthenia gravis.IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus.CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.Treatment strategies for autoimmune encephalitis.IL-2 and Beyond in Cancer Immunotherapy.Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy.SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival.Low-dose IL-2 expands CD4+ regulatory T cells with a suppressive function in vitro via the STAT5-dependent pathway in patients with chronic kidney diseases.Regulatory T Cells As Supporters of Psychoimmune Resilience: Toward Immunotherapy of Major Depressive Disorder.Low-dose IL-2 therapy - a complex scenario that remains to be further explored.Clinical trials: The rise of IL-2 therapy - a novel biologic treatment for SLE.Protective Role of Myeloid Cells Expressing a G-CSF Receptor Polymorphism in an Induced Model of Lupus.Site-Mutation of Hydrophobic Core Residues Synchronically Poise Super Interleukin 2 for Signaling: Identifying Distant Structural Effects through Affordable Computations.Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus.Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.Signal Transducer and Activator of Transcription 3 Hyperactivation Associates With Follicular Helper T Cell Differentiation and Disease Activity in Rheumatoid Arthritis.
P2860
Q33604206-D08F81FB-45DA-466A-BF81-4DBCD3D2CEBBQ33620555-FE5E389E-44E7-4E80-AD78-90946BC183BFQ33742139-C1D91BA5-4CEC-4450-9E9B-9A9C79040ACDQ37377103-AF36E022-02F1-4281-8978-DA2CE0E1F28DQ38616032-B9107DFB-D267-4029-80C5-791D04476C83Q38722252-EB05830C-D87F-45C9-8427-902576FEAD4FQ38751056-C0BE4973-4FBB-4309-A0A1-D875134214D1Q38972466-25EA7E0E-0B9B-488C-8374-E7744FF30B43Q39076924-C3A38839-1C49-4DDE-9B15-B3B75CAD7D51Q39088684-86BE13F3-4B27-45CB-A59E-BC64AFAECEFAQ39163678-B0A2E92B-2EFC-49E2-8FCC-92B706455953Q39164953-13E1D528-8945-4337-B215-D394D92B723EQ39175811-4130A4A9-E92E-4A70-A6DF-0BF814BED0F8Q39379152-89E4E54D-46B6-42EF-A0BC-96348555AA20Q40218294-A3D62ABF-6E76-46AF-A91E-BE62A86595D2Q40354412-560D87B5-C8E5-4892-8746-A52724FDD0FCQ45066685-194A1E66-5188-4B70-A5F4-63AD5BAC27A1Q45797119-4E44EEB7-67B1-48E9-8AD9-6C610480F30CQ47099680-72DF7FCE-C35D-4068-864A-B3962ED06FD5Q47158394-C1C07391-1A51-460A-9F93-62D89A53CA55Q47219879-8F379145-6251-4BD5-96C5-3E224E505C65Q47578102-5B510F33-78D1-468C-910B-E2A27702E019Q48128911-A24FF16A-28BE-49C6-8376-D5CCCAF08D15Q48186167-87B87968-F14F-4174-A5C7-230514CBD54EQ48228475-2DE1D1D2-64A6-4B7D-A1A1-687C5942F8BDQ48282629-4FC29AAD-9010-4824-B59D-F7655E24DB18Q49213573-F1A35BE2-CC28-4085-AE1C-22B622F4937DQ50004232-E1FA18EA-B42B-4E6C-AB4C-2ED56FCA41EDQ50068095-F7E7CF7C-AD4E-42A1-8486-8D49291D3581Q50115047-C7B222F3-92AB-49DC-846F-8C2237B7F141Q51095965-D9058A52-9E8F-4A32-B102-D7E059E16BB6Q52605507-02CA3FA7-2983-495E-A8CD-DAEE8EA17306Q52608611-127B37B2-0CE0-43EE-BEA4-FFC51A914126Q52654326-193FC26F-36F7-406D-8ED7-D5496897D142Q54482726-536DD116-6389-4F7C-9E51-20A8065BD139Q54957133-7DD207C4-525C-4585-9871-A9C7479FF2A9Q54960290-3FAA8302-3C07-4CB7-A4E7-43CEBCA0810AQ55096330-12FBCA35-1255-4F8C-9B84-61557696CF86Q55163735-D8830F45-3823-4D24-8AEF-A2DA17698508Q55261674-0A7D27C1-AE1C-4A40-A6F4-E6670F325B1E
P2860
Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Low-dose interleukin-2 treatme ...... systemic lupus erythematosus.
@en
type
label
Low-dose interleukin-2 treatme ...... systemic lupus erythematosus.
@en
prefLabel
Low-dose interleukin-2 treatme ...... systemic lupus erythematosus.
@en
P2093
P50
P356
P1433
P1476
Low-dose interleukin-2 treatme ...... h systemic lupus erythematosus
@en
P2093
Chuanhui Xu
Haihong Yao
Jianping Guo
Jinhong Feng
P2888
P304
P356
10.1038/NM.4148
P407
P577
2016-08-08T00:00:00Z